Virta Health Study Suggests Nutrition-Based Metabolic Care May Significantly Reduce Risk of Chronic Kidney Disease
Virta Health, a leader in reversing metabolic disease through individualized nutrition-based care, has announced the publication of a major peer-reviewed study demonstrating that chronic kidney disease (CKD)—one of the most serious and costly complications of diabetes and obesity—may be more preventable than previously believed. Published in the journal Diabetes, Obesity and Metabolism, the research represents one of the largest real-world evaluations of nutrition-focused metabolic care, following more than 10,000 patients over a five-year period.
The findings indicate that adults living with type 2 diabetes or obesity who participated in Virta’s personalized metabolic treatment program experienced substantially lower rates of chronic kidney disease compared with carefully matched individuals receiving standard medical care. Most notably, the study found a 62% reduction in the incidence of advanced kidney disease among participants receiving Virta’s intervention, highlighting the potential of addressing metabolic health at its source rather than focusing solely on treating complications after they develop.
Addressing One of Healthcare’s Most Serious Challenges
Chronic kidney disease is widely recognized as one of the most devastating long-term consequences of metabolic disorders. The condition affects an estimated one in every ten adults in the United States, while more than 40% of individuals living with type 2 diabetes are expected to develop some degree of kidney damage during their lifetime.
One of the greatest challenges associated with CKD is that it often progresses silently. Many patients experience few or no noticeable symptoms until kidney function has already deteriorated significantly. By the time the disease is diagnosed, treatment options may be limited, and patients face an increased risk of serious complications, including cardiovascular disease, stroke, hospitalization, kidney failure, dialysis, transplantation, and premature death.
Beyond its impact on patients, chronic kidney disease also places an enormous financial burden on healthcare systems. Dialysis treatment alone costs Medicare approximately $95,000 annually for each patient, while the total annual healthcare expenditures related to CKD exceed $170 billion, making kidney disease one of the most expensive chronic illnesses to manage.
Largest Real-World Study of Its Kind
The newly published research analyzed healthcare outcomes from more than 22,000 individuals using one of the nation’s largest healthcare claims databases, the Komodo Healthcare Map™.
Investigators matched 11,077 adults enrolled in Virta’s individualized nutrition-based metabolic care program with an equal number of similar patients receiving conventional medical treatment. Participants were matched according to demographic and clinical characteristics to ensure meaningful comparisons between the two groups.
Researchers then monitored kidney-related outcomes over a follow-up period of up to five years, allowing them to evaluate whether comprehensive metabolic care could influence the development and progression of chronic kidney disease in real-world clinical settings.
Unlike traditional randomized clinical trials that often involve highly controlled environments, this retrospective cohort study reflects outcomes achieved in routine clinical practice, providing valuable insight into how nutrition-focused care performs across diverse patient populations.
Significant Reduction in Kidney Disease Risk
According to the study, patients participating in Virta’s individualized metabolic care consistently demonstrated lower rates of chronic kidney disease across multiple stages of disease progression.
Among the most important findings were:
- A 36% lower incidence of chronic kidney disease overall.
- A 43% reduction in Stage 3 or higher CKD.
- A 62% reduction in advanced Stage 4 or higher kidney disease.
- No increase in major kidney-related safety events.
These improvements were observed despite the growing use of modern kidney-protective medications among patients receiving standard care, suggesting that comprehensive metabolic management may provide additional protective benefits beyond pharmacological treatment alone.
The results reinforce the importance of addressing the underlying metabolic dysfunction associated with diabetes and obesity rather than simply treating individual complications after they arise.
Treating the Root Cause
Virta’s care model focuses on improving metabolic health through individualized nutritional therapy delivered via telehealth, physician oversight, continuous biomarker monitoring, and personalized coaching.
Rather than relying exclusively on medications to control symptoms, the program aims to improve insulin resistance, stabilize blood sugar, reduce body weight, and restore healthier metabolic function.
Because diabetes and obesity are major drivers of kidney disease, improving these underlying conditions may reduce ongoing stress placed on the kidneys and slow disease progression before irreversible damage occurs.
Dr. Adam Wolfberg, Chief Medical Officer at Virta Health, said the findings challenge long-held assumptions about the inevitability of kidney disease among patients with metabolic disorders.
According to Wolfberg, chronic kidney disease has traditionally been viewed as an expected consequence of diabetes and obesity. However, the new study demonstrates that individualized metabolic care centered on nutrition was associated with dramatically lower rates of kidney disease—even after accounting for the widespread use of today’s leading kidney-protective medications.
He added that improving metabolic health at its source has the potential to fundamentally change the long-term course of chronic disease.
Reassuring Safety Findings
The study also addressed one of the most frequently discussed concerns surrounding carbohydrate-restricted nutritional approaches.
Some clinicians have questioned whether reducing carbohydrate intake might negatively affect kidney health or increase the risk of complications such as kidney stones or metabolic disturbances.
Researchers specifically evaluated several kidney-related safety outcomes, including:
- Kidney stones
- Metabolic acidosis
- Diabetic ketoacidosis
- Gout
Across each of these outcomes, investigators found no increase in claims-based diagnoses among patients participating in Virta’s individualized treatment program compared with those receiving standard care.
These findings provide additional reassurance regarding the long-term safety profile of carbohydrate-reduced nutritional interventions when delivered under appropriate medical supervision.
Rethinking Nutrition and Kidney Disease
Lead investigator Dr. Richard Johnson, Professor Emeritus at the University of Colorado, believes the study contributes to an evolving understanding of nutrition’s role in kidney disease.
For many years, dietary recommendations for individuals at risk of kidney disease emphasized limiting protein intake as a primary strategy for preserving kidney function.
However, growing evidence suggests that excess consumption of refined carbohydrates may play a much larger role in the progression of kidney disease than previously recognized.
According to Dr. Johnson, the current findings provide strong real-world evidence that carbohydrate-reduced nutritional therapy is associated with substantially lower rates of chronic kidney disease while also slowing progression across multiple disease stages.
Although further research will continue exploring the biological mechanisms involved, the study strengthens the scientific foundation supporting nutrition as an important component of kidney disease prevention.
Expanding Evidence for Metabolic Care
The kidney disease study adds to an expanding body of research examining the broader health benefits associated with improving metabolic function.
Previous peer-reviewed investigations involving Virta’s individualized care model have reported improvements in several conditions linked to metabolic dysfunction, including:
- Chronic inflammation
- Fatty liver disease
- Cardiovascular risk factors
- Type 2 diabetes management
- Obesity
- Certain aspects of pancreatic cancer treatment
Collectively, these findings support a growing shift within medicine toward treating the metabolic drivers underlying multiple chronic diseases rather than addressing each complication individually.
Researchers increasingly recognize that insulin resistance, chronic inflammation, and impaired metabolic health contribute to numerous diseases affecting different organ systems.
By improving these core biological processes, comprehensive metabolic care may reduce the risk of developing multiple chronic conditions simultaneously.
Leveraging Large-Scale Real-World Data
The study utilized the Komodo Healthcare Map™, one of the largest healthcare claims databases available in the United States.
This resource enabled researchers to examine long-term clinical outcomes across a broad patient population while minimizing selection bias through carefully matched comparison groups.
Although retrospective studies cannot establish definitive cause-and-effect relationships in the same way randomized clinical trials can, they provide valuable evidence regarding treatment effectiveness in everyday healthcare settings.
The large sample size and extended follow-up period strengthen confidence in the observed associations between individualized metabolic care and reduced kidney disease risk.
Virta Health believes the study reinforces the importance of nutrition-based interventions as part of comprehensive chronic disease management.
The company continues to expand research evaluating how personalized metabolic care may influence additional health outcomes beyond diabetes and obesity, with a growing focus on preventing the complications that drive healthcare costs and reduce patients’ quality of life.
As chronic kidney disease continues to affect millions of people worldwide, these findings suggest that addressing metabolic dysfunction through individualized nutritional therapy may offer a promising strategy for reducing disease incidence, slowing progression, and improving long-term patient outcomes.
While additional prospective studies will further clarify the relationship between metabolic care and kidney protection, the newly published research provides compelling real-world evidence that improving metabolic health may significantly reduce the burden of one of healthcare’s most challenging chronic diseases, offering new hope for patients living with type 2 diabetes, obesity, and other metabolic disorders.
About Virta Health
Virta Health is the leader in reversing metabolic disease. Through its metabolic health platform, Virta combines individualized nutrition therapy, deep experience in GLP-1 optimization, expert clinical care, and AI-enhanced technology to deliver personalized support at scale. Together, this approach empowers members to build longer, healthier lives, while reducing or eliminating the need for medications. Virta partners with the nation’s largest employers, payers, and pharmacy benefit managers to improve the health of their members while reducing costs. Headquartered in Denver, Colorado, Virta is on a bold mission to reverse metabolic disease in one billion people.